

<p>Substitute for FORM 1449A/B/PTO</p> <h2 style="text-align: center; margin: 20px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 10px 0;">(Use as many sheets as necessary)</p> <p style="text-align: center;">Sheet 1 of 1</p>	<p style="text-align: center;">Complete if Known</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number:</td> <td>10/567766</td> </tr> <tr> <td>Filing Date:</td> <td>February 10, 2006</td> </tr> <tr> <td>First Named Inventor:</td> <td>HASEGAWA, Hideki</td> </tr> <tr> <td>Group Art Unit:</td> <td>1642</td> </tr> <tr> <td>Confirmation Number:</td> <td>5560</td> </tr> <tr> <td>Examiner Name:</td> <td></td> </tr> <tr> <td>Attorney Docket Number:</td> <td>43512-103808</td> </tr> </table>	Application Number:	10/567766	Filing Date:	February 10, 2006	First Named Inventor:	HASEGAWA, Hideki	Group Art Unit:	1642	Confirmation Number:	5560	Examiner Name:		Attorney Docket Number:	43512-103808
Application Number:	10/567766														
Filing Date:	February 10, 2006														
First Named Inventor:	HASEGAWA, Hideki														
Group Art Unit:	1642														
Confirmation Number:	5560														
Examiner Name:															
Attorney Docket Number:	43512-103808														

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number				

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	B F	JP	2002516294		Loeb Health Research Institute at the Ottawa Hospital	Jun. 4, 2002		X ⁺

OTHER - NON PATENT LITERATURE DOCUMENTS					Translation	
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.			Yes	No**
	B G	Harandi et al., "Recent developments in mucosal immunomodulatory adjuvants," <i>Cur. Opin. Investigational Drugs</i> , 4(2): 156-161 (2003).				
	B H	Holmgren et al, "Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA," <i>Expert Rev. of Vaccines</i> , 2(2): 205-217 (2003).				
	B I	Jiang et al., "Poly(I•C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFκB and MAP kinase is through an interleukin-1 receptor-associate kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR," <i>J. Bio. Chem.</i> , 278(25): 16713-16719 (2003).				
	B J	Maeyama et al. "Effects of Recombinant Cholera Toxin B Subunit on IL-1β Production by Macrophages in Vitro," <i>Microbiol. Immunol.</i> , 46(9): 593-599 (2002).				
	B K	Tamura, "Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine," <i>Eur. J. Immunol.</i> , 22(2): 477-481 (1992).				
	B L	Wong et al., "Prophylactic and Therapeutic Efficacies of Poly (IC•LC) against Respiratory Influenza A virus Infection in Mice," <i>Antimicro. Agents and Chemotherapy</i> , 39(11): 2574-2576 (1995).				

CHDS01 SDEVADAS 463679v1

EXAMINER	DATE CONSIDERED
----------	-----------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).